Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety
| Autor: | M. I. Volkova, Ya. V. Gridneva, A. S. Olshanskaya |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 10, Pp 146-154 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2019-10-146-154 |
| Popis: | Cabazitaxel, an antineoplastic agent from the third generation taxan group, has demonstrated efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. This article is devoted to a critical analysis of studies on the use of cabazitaxel in this category of patients and key aspects of management of treatment-related toxicity. The authors also reviewed possible scenarios for the use of cabazitaxel in the sequential therapy of mCRPC, including androgen receptor signalling inhibitors and systemic radiotherapy. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|